BPCEditorially reviewed · 1. Mai 2026

BPC-157

Also known as Body Protection Compound 157, PL 14736, Bepecin et al.

not approvedEvidence · preclinical3 studies citedWADA-listed

Structure · schematic

Peptide chain of 15 amino acids · BPC

Sequence

GEPPPGKPADDAGLV

Schematic representation of the amino acid chain — not a chemical structural formula. Each node represents one amino acid (shown truncated).

Research areas*

Recovery
Immunomodulation

* Contexts in which the peptide has been scientifically studied — not assured or recommended effects.

§ 1

Mechanism of action

  • BPC-157 is a synthetic pentadecapeptide derived from a partial sequence of a human gastric juice protein.
  • In preclinical studies, interactions with the NO system (nitric oxide signalling pathway) and with the EGR1 and VEGFR2 receptor pathways have been described, which may mediate angiogenic and cytoprotective effects.
  • The precise mechanisms of action in humans have not been conclusively established.
§ 2

Research status

  • BPC-157 has been studied predominantly in animal models (rodents), particularly in the context of gastrointestinal lesions, tendon and muscle tissue, and wound healing.
  • In these preclinical models, signs of accelerated tissue regeneration and gastroprotective effects were described.
  • Controlled human trials are largely lacking; the substance is not in active Phase II/III clinical programmes.
  • A Phase II study of the oral form (PL 14736) in ulcerative colitis was discontinued; results were not conclusively published.

Evidence level

PreclinicalEarly clinicalEstablished
§ 3

Cited studies

  1. 2015
    Pentadecapeptide BPC 157 reduces bleeding and thrombocytopenia after amputation in rats treated with heparin, warfarin, l-NAME and l-arginine
  2. 2018
    BPC 157 and Standard Angiogenic Growth Factors: Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle, and Bone Healing
  3. 2021
    Stable gastric pentadecapeptide BPC 157 in clinical trials as a means of treatment for both IBD and IBS – What is the current state?
§ 4

Known risks

  • 01No controlled human studies — safety profile in humans not established
  • 02Potential interactions with the coagulation system (described in animal models)
  • 03Unknown long-term consequences of repeated use
  • 04Product quality cannot be verified from unapproved sources (contaminants, incorrect concentrations)
  • 05Legal risk: possession and import may be punishable
§ 5

Frequently asked questions

What is BPC-157?

BPC-157 is a synthetic pentadecapeptide derived from a partial sequence of a human gastric juice protein.

What type of peptide is BPC-157?

BPC-157 belongs to the BPC class.

Is BPC-157 legal in Germany?

BPC-157 is not approved as a medicine in Germany. Obtaining it outside clinical studies is legally problematic.

Where can I buy BPC-157?

Peptica sells nothing and names no sources. BPC-157 is "not approved" in Germany; obtaining unapproved substances outside clinical studies is illegal and carries quality and safety risks.

Is BPC-157 banned in sport (WADA)?

Yes. BPC-157 is on the WADA Prohibited List and is therefore banned in competitive sport.

What are the known risks of BPC-157?

Documented risks include: No controlled human studies — safety profile in humans not established; Potential interactions with the coagulation system (described in animal models). This is not a complete safety assessment and not medical advice — see the risks section for the full list.

How well researched is BPC-157?

The evidence is classified as “preclinical”. 3 studies are cited on this page.

What is the molecular weight of BPC-157?

BPC-157 has a molar mass of about 1419.5 Da.

Which peptides are related to BPC-157?

Closely related entries: TB-500. A direct side-by-side comparison is available via the compare function.

Related entries

Legal status

Germany

not approved

Austria

not approved

Switzerland

not approved

EU

not approved

USA

not approved

Canada

not approved
WADA-listed · S2

Legal status varies by country and can change. This is not legal advice.

Sources & methodology

  • 3 peer-reviewed studies cited, linked to PubMed where available.
  • Molecular data verified against PubChem and primary literature. PubChem CID 9941957
  • Editorial standard: no dosage guidance, no sources, evidence level stated explicitly.

Last editorially reviewed: 1 May 2026

Legal assessment

Since 2022, BPC-157 has been on the WADA Prohibited List (section S2: peptide hormones, growth factors and related substances). It is not approved as a medicine in the EU, Germany, Austria or Switzerland. Importing it as a so-called research chemical is a legal grey area and may fall under the German Medicines Act (AMG). Conservative assessment: not to be obtained.

Important notice

This site is intended solely for factual, scientifically oriented information about peptides. It does not constitute medical advice, does not replace a consultation with a doctor and contains no recommendations for use in humans.

This site does not sell any substances and names no sources for unapproved substances. For medical questions, please consult qualified medical professionals.

Anzeige

Reserviert für sorgfältig ausgewählte Partner — Telemedizin, Diagnostik, legale topische Anwendungen.

§ 6

Community notes

Note: These posts are user opinions and not medical advice. Posts containing dosages, therapeutic claims or purchase recommendations are removed. All entries are manually reviewed before publication.